Clinical trials: Retinal Pigment Epithelial Detachment
Pigment Epithelial Detachment
Aflibercept in Patients With Pigment Epithelial Detachments (PED)
Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment…
- Trial name
- NCT03370380
- Testing
- Aflibercept
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- University Hospital Muenster
Pigment Epithelial Detachment
Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
- Trial name
- NCT00976222
- Testing
- intravitreal injection with ranibizumab
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Muenster
Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration
Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
Primary Objectives: To assess the efficacy of intravitreal administered Eylea in preventing visual loss in subjects with a retinal pigment epithelial detachment (PED) subtype of neovascular age-related macular degeneration (AMD)…
- Trial name
- NCT02142296
- Testing
- Eylea
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Wet Macular Degeneration, Macular Degeneration
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy.
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Trial name
- HiPED (NCT01189019)
- Testing
- ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anne Fung MD
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Age Related Macular Degeneration, Pigment Epithelial Detachment
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
- Trial name
- ROLL (NCT01670162)
- Testing
- Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tennessee Retina
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Retinal Pigment Epithelial Detachment With Vascularization, Age Related Macular Degeneration
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
This is a pilot, single-center, interventional clinical trial in which subjects will receive 16 Gy of IRay treatment and Lucentis, followed by Lucentis treatment as needed.
- Trial name
- NCT01521819
- Testing
- Iray, Lucentis
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.
Retinal Pigment Epithelial Detachment
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
- Trial name
- NCT00749021
- Testing
- Ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Clement K. Chan
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Age-related Macular Degeneration, Pigment Epithelial Detachment
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis).
- Conditions
- Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
- Trial name
- DETAIL (NCT00590694)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pacific Eye Associates
Pigment Epithelial Detachment
Lucentis to Treat Pigment Epithelial Detachment
Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.
- Trial name
- NCT00841581
- Testing
- Ranibizumab
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's